IRIDEX (IRIDEX) Total Liabilities

: $24.91 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

IRIDEX's Total Liabilities for the quarter that ended in Dec. 2023 was $24.91 Mil.

IRIDEX's quarterly Total Liabilities declined from Jun. 2023 ($23.49 Mil) to Sep. 2023 ($22.89 Mil) but then increased from Sep. 2023 ($22.89 Mil) to Dec. 2023 ($24.91 Mil).

IRIDEX's annual Total Liabilities declined from Dec. 2021 ($25.39 Mil) to Dec. 2022 ($25.06 Mil) and declined from Dec. 2022 ($25.06 Mil) to Dec. 2023 ($24.91 Mil).

IRIDEX Total Liabilities Historical Data

The historical data trend for IRIDEX's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

12.11

10.60

25.39

25.06

24.91

IRIDEX Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities																25.06	25.10	23.49	22.89	24.91

IRIDEX Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IRIDEX's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.974	+	(1.751	+	0.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.025	+	0)
	=	24.91

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	34.436	-	9.522
	=	24.91

IRIDEX's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.974	+	(1.751	+	0.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	10.025	+	0)
	=	24.91

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	34.436	-	9.522
	=	24.91

IRIDEX Total Liabilities Related Terms

Thank you for viewing the detailed overview of IRIDEX's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IRIDEX (IRIDEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1212 Terra Bella Avenue, Mountain View, CA, USA, 94043

Website

https://www.iridex.com

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Executives

Nandini Devi	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss	director	C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp	10 percent owner	75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp	10 percent owner	111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous	director	C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda	director	402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer	officer: COO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne	director
Robert A Gunst	director
David Bruce	director, officer: President and CEO	1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum	director
Romeo R Dizon	other: Vice President and Controller	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043